<DOC>
	<DOC>NCT01347346</DOC>
	<brief_summary>This is a phase I/II study to evaluate the safety and efficacy of Hematopoietic Stem Cell genetherapy for the Wiskott-Aldrich Syndrome.</brief_summary>
	<brief_title>Gene Therapy for WAS</brief_title>
	<detailed_description>This clinical trial is an ex vivo gene therapy trial. The investigational product corresponds to autologous CD34+ cells transduced with a lentiviral vector harboring the human WASP gene.</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Wiskott-Aldrich Syndrome</mesh_term>
	<criteria>males of all ages severe WAS (clinical score 35) or absence of WAS protein in peripheral blood mononuclear cells determined by Western blotting and flow cytometry molecular confirmation by WAS gene DNA sequencing lack of HLAgenotypically identical bone marrow after 3 month search lack of a 10/10 or 9/10 antigen HLAmatched unrelated donor after 3 month search lack of a HLAmatched cord blood after 3 month search parental, guardian, patient signed informed consent/assent willing to return for followup only for patients who have received previous allogenic hematopoietic stem cell transplant: failed allogenic hematopoietic stem cell transplant contraindication to repeat transplantation patient with HLAgenotypically identical bone marrow patient with 10/10 or 9/10 antigen HLAmatched unrelated donor or with HLAmatched cord blood contraindication to leukapheresis contraindication to bone marrow harvest contraindication to administration of conditioning medication HIV positive patient</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Wiskott-Aldrich Syndrome</keyword>
	<keyword>Primary immune deficiency</keyword>
	<keyword>ex vivo gene therapy</keyword>
	<keyword>hematopoietic stem cells</keyword>
</DOC>